Stockscreener 앱 받기
1.93
0.52%
-0.01
시장 영업 전:
2.00
0.07
+3.63%
Alaunos Therapeutics Inc 주식(TCRT)의 최신 뉴스
CEO Holger Weis takes Alaunos Therapeutics, Inc. (TCRT) stock instead of salary - Stock Titan
Alaunos Therapeutics, Inc. (TCRT) director receives 8,138-share board fee grant - Stock Titan
Alaunos Therapeutics (TCRT) director gets 8,789-share equity grant in lieu of fees - Stock Titan
Alaunos Therapeutics (TCRT) director granted 8,463 shares for board fees - Stock Titan
Alaunos Therapeutics Inc (TCRT) Cash Flow - TradingKey
TradingKey - TradingKey
Alaunos Therapeutics Inc (TCRT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Alaunos Therapeutics Inc (TCRT) Institutional Confidence - TradingKey
Alaunos Therapeutics, Inc. Revenue Breakdown – NASDAQ:TCRT - TradingView
Alaunos Therapeutics Inc (TCRT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
TCRT|Alaunos Therapeutics Inc|Price:1.940|Chg%:+0.020 - TradingKey
Alaunos Therapeutics Inc (TCRT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Alaunos Therapeutics (TCRT) Edges Higher as Stock Holds Above Key SupportMACD Signal Stocks - dars.gov.et
Price to earnings forward of Alaunos Therapeutics, Inc. – NASDAQ:TCRT - TradingView
Price to book forward of Alaunos Therapeutics, Inc. – NASDAQ:TCRT - TradingView
Alaunos Therapeutics Reports Encouraging Early Obesity Drug Results - Stocktwits
Enterprise value to revenue forward of Alaunos Therapeutics, Inc. – NASDAQ:TCRT - TradingView
Price to sales forward of Alaunos Therapeutics, Inc. – NASDAQ:TCRT - TradingView
MSN Money - MSN
Form 4 Alaunos Therapeutics Inc For: 2 July By Investing.com - Investing.com Canada
Stock grant to Alaunos (TCRT) CEO issued in lieu of salary - Stock Titan
Alaunos Therapeutics Inc (TCRT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
TCRT Q4 2023 Earnings: Miss on EPS as Alaunos Continues Pre-Clinical DevelopmentEarnings Per Share - dars.gov.et
Alaunos Reports New Preclinical ALN1003 Data Showing Lower Liver - The National Law Review
Alaunos Reports New Preclinical ALN1003 Data Showing Lower Liver Weight After Adjustment for Body Fat Percentage in 48-Day DIO Mouse Study - markets.businessinsider.com
Alaunos Reports New Preclinical Liver Data for ALN1003 - TipRanks
Alaunos Therapeutics (TCRT) posts new ALN1003 mouse liver and metabolic findings - Stock Titan
12 Health Care Stocks Moving In Monday's Pre-Market SessionUniverse Pharmaceuticals (NASDAQ:UPC), Deco - Benzinga
Alaunos Therapeutics, Inc. Actuals & Estimates (NASDAQ:TCRT) - TradingView
TCRT Q4 2023 Earnings: EPS Misses Estimates Amid Ongoing Clinical DevelopmentEstimate Dispersion - dars.gov.et
Alaunos Therapeutics Inc (TCRT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Alaunos Therapeutics (TCRT) CEO takes 7,761-share stock grant in lieu of salary - Stock Titan
TCRT Q4 2023 Earnings: EPS Miss Reflects Clinical-Stage Operational HeadwindsNew Analyst Coverage - dars.gov.et
Alaunos Therapeutics Inc (TCRT) Valuation: PE, PB & Fair Value Analysis - TradingKey
Alaunos Therapeutics Inc (TCRT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Alaunos Therapeutics Inc (TCRT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
TCRT Q4 2023 Earnings: EPS Miss Amid Ongoing Clinical DevelopmentEarnings Surprise Report - newsline.com
Number of shareholders of Alaunos Therapeutics, Inc. – NASDAQ:TCRT - TradingView
TCRT Q4 2023 Earnings: EPS Misses Estimates, No Revenue Reported, Stock DeclinesEarnings Stability Report - newsline.com
Alaunos Therapeutics (TCRT) Declines 6.56% as Stock Tests Key Support Near $2.17Swing Trade Setups - newsline.com
TCRT Q4 2023 Earnings: Wider-Than-Expected Loss on Lack of RevenueEstimate Dispersion - dars.gov.et
Alaunos Therapeutics (TCRT) falls on cash concerns, Nasdaq delisting risk - Bez Kabli
Eli Lilly continues genetic medicine push with $1.9bn Ascidian partnership - Pharmaceutical Technology
Alaunos Therapeutics (TCRT) Declines 4.18% as Biotech Sector Pressure Tests Key Support LevelsQuality ETF - newsline.com
TCRT Q4 2023 Earnings: EPS Misses Estimates Amid Continued Clinical-Stage Cash BurnGuidance Update - dars.gov.et
Alaunos Therapeutics Q4 2023 Earnings: EPS Miss Widens as Pre-Revenue Biotech Faces Continued Headwinds - DonanımHaber
Alaunos Therapeutics (TCRT) Dips 6.86% as Stock Approaches Critical Support LevelChaikin Flow - The Legal Advocate
TCRT Q4 2023 Earnings: Wider-Than-Expected Loss as Pre-Revenue Biotech Advances PipelineEarnings Season Outlook - newsline.com
TCRT Q4 2023 Earnings: Loss Wider Than Estimates but Stock ClimbsGuidance Accuracy Score - dars.gov.et
Alaunos Therapeutics (TCRT) CEO takes 3,700 shares instead of salary - Stock Titan
Alaunos reports positive preclinical obesity drug results across weight, liver, insulin markers - MSN
1.97%
0.83%
자본화:
|
볼륨(24시간):